Substance / Medication

Nalmefene hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Green and blue space exposure and non-communicable disease related hospitalizations: A systematic review.
Luque-García L, Muxika-Legorburu J, Mendia-Berasategui O et al. · Environ Res · 2024
PMID: 38157973Meta-Analysis
Respiratory dysfunction in degenerative cervical myelopathy: A systematic review.
Elliott Lorcan, Li Michael, Gharooni Aref-Ali et al. · J Clin Neurosci · 2024
PMID: 38237493Meta-Analysis
Exposure to outdoor particulate matter and risk of respiratory diseases: a systematic review and meta-analysis.
Nakhjirgan Pegah, Kashani Homa, Kermani Majid · Environ Geochem Health · 2023
PMID: 38153542Meta-Analysis
Nalmefene Hydrochloride: Potential Implications for Treating Alcohol and Opioid Use Disorder.
Green MeShell, Veltri Charles A, Grundmann Oliver · Subst Abuse Rehabil · 2024
PMID: 38585160ReviewFull text (PMC)
Efficacy of Nalmefene Hydrochloride Injection Combined With Hemoperfusion in the Treatment of Acute Drug Poisoning.
Zhou Wei, Li Xiang, Jiang Jiamei et al. · Ther Drug Monit · 2025
PMID: 40903175Other
Effect of Different Absorption Enhancers on the Nasal Absorption of Nalmefene Hydrochloride.
Zhang Ting, Li Meng, Han Xiaolu et al. · AAPS PharmSciTech · 2022
PMID: 35578146Preclinical
Effects of nalmefene hydrochloride on TLR4 signaling pathway in rats with lung ischemia-reperfusion injury.
Zhang N-L, Wang H-Q, Yang J et al. · Eur Rev Med Pharmacol Sci · 2020
PMID: 31957861Preclinical
The permeation of nalmefene hydrochloride across different regions of ovine nasal mucosa.
Du Gani, Gao Yongliang, Nie Shufang et al. · Chem Pharm Bull (Tokyo) · 2006
PMID: 17139110Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Nalmefene hydrochloride (substance)
SNOMED CT
412252005
UMLS CUI
C0771297

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.